Previous 10 | Next 10 |
2024-01-04 16:51:37 ET DENVER, Colo., Jan. 4, 2024 ( www.247marketnews.com )- Dermata Therapeutics, Inc. (NASDAQ: DRMA) announced, after today’s market close, that it was issued a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis, entitled “Comp...
- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company is currently discussing partnership opportunities to advance development of DMT410 - - In 2022, the Japanese prevalence of hyperhid...
- About 550 patients will be treated once weekly for 12 weeks - - STAR-1 topline results expected in first quarter of 2025 - - Acne affects about 50 million patients in the U.S. - SAN DIEGO, CA / ACCESSWIRE / December 20, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Der...
2023-12-18 14:46:47 ET Top 3 Strategies to Use for Trading Penny Stocks Next Year Penny stocks are a popular but risky investment option due to their potential for high returns. Having a trading strategy with penny stocks is important in order to minimize the risk involved and maximize ...
2023-12-08 08:07:30 ET More on Dermata Therapeutics Seeking Alpha’s Quant Rating on Dermata Therapeutics Historical earnings data for Dermata Therapeutics Financial information for Dermata Therapeutics For further details see: Dermata Therapeutics ...
- DMT310 Phase 3 STAR-1 (Spongilla Treatment of Acne Research) clinical trial will evaluate the efficacy and safety of once-weekly treatments of DMT310 for 12 weeks in moderate-to-severe acne patients - - Topline results from STAR-1 clinical trial expected in Q1 2025 - - DMT310, if appr...
2023-11-10 07:49:29 ET More on Dermata Therapeutics Seeking Alpha’s Quant Rating on Dermata Therapeutics Historical earnings data for Dermata Therapeutics Financial information for Dermata Therapeutics For further details see: Dermata Therapeutics ...
- Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedback from FDA on its End of Phase 2 meeting package in June 2023 - - Completed start-up activities to support DMT310 Phase 3 STAR-1 clinical trial in acne - SAN...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Dermata Therapeutics Inc. (DRMA) is expected to report for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
Koninklijke KPN NV (KKPNF) is expected to report for Q4 2023 ECA Marcellus Trust I Unit (ECTM) is expected to report for Q4 2023 San Juan Basin Royalty Trust (SJT) is expected to report for Q4 2023 Avenir Wellness Solutions Inc (AVRW) is expected to report for Q4 2023 Carmell Corp...